Merck & Co. Inc. (NYSE:MRK) – Merck Announces Presentation of Interim Data from Phase 1B Study of MK-3475, Investigational anti-PD-1 Immunotherapy, in Previously-Treated Patients with Non-Small Cell Lung Cancer (NSCLC) at 15th World Conference on Lung Cancer

[at noodls] – WHITEHOUSE STATION, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from a Phase 1B trial (PN001) evaluating … Read . . . → Read More: Merck & Co. Inc. (NYSE:MRK) – Merck Announces Presentation of Interim Data from Phase 1B Study of MK-3475, Investigational anti-PD-1 Immunotherapy, in Previously-Treated Patients with Non-Small Cell Lung Cancer (NSCLC) at 15th World Conference on Lung Cancer Similar posts: Can Eli Lilly Earnings Keep Up With Merck and Pfizer? – Merck & Co. Inc. (NYSE:MRK) [at Motley Fool] – Like many of its peers,... Merck – Little Appeal Despite Recently Announced Cost Cuts – Merck & Co. Inc. (NYSE:MRK) [at Seeking Alpha] – Shares of Merck ( MRK )... Company Update: Johnson & Johnson (NYSE:JNJ) – AstraZeneca to co-promote J&J prostate cancer drug in Japan [Reuters - UK Focus] – AstraZeneca has signed a deal...